晚期膀胱癌PD-1/PD-L1抑制剂治疗的研究进展(5)
[23] Heery CR，O′sullivan-coyne G，Madan RA，et al. Avelumab for metastatic or locally advanced previously treated solid tumors(JAVELIN Solid Tumor)：a phase 1a，multicohort，dose-escalation trial [J]. Lancet Oncol，2017，18(5)：587-598.
[24] Apolo AB，Infante JR，Balmanoukian A，et al. Avelumab，an anti-programmed death-ligand 1 antibody，in patients with refractory metastatic urothelial carcinoma：results from a multicenter，phase Ⅰb study [J]. J Clin Oncol，2017，35(19)：2117-2124.
[25] Khoja L，Butler MO，Kang SP，et al. Pembrolizumab [J]. J Immuno Ther Cancer，2015，3(1)：36.
[26] Bellmunt J，De wit R，Vaughn DJ，et al. KEYNOTE-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma [J]. New Engl J Med，2017，376(11)：1015-1026.
[27] Michot JM，Bigenwald C，Champiat S，et al. Immune-related adverse events with immune checkpoint blockade：a comprehensive review [J]. Eur J Cancer，2016，54：139-148.
[28] Weber JS，Kahler KC，Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab [J]. J Clin Oncol，2012，30(21)：2691-2697.
[29] Champiat S，Lambotte O，Barreau E，et al. Management of immune checkpoint blockade dysimmune toxicities：a collaborative position paper [J]. Ann Oncol，2015，27(4)：559-574.
(收稿日期：2019-07-24 本文編辑：李亚聪), http://www.100md.com(李彦泽 王磊 陈志远)
[24] Apolo AB，Infante JR，Balmanoukian A，et al. Avelumab，an anti-programmed death-ligand 1 antibody，in patients with refractory metastatic urothelial carcinoma：results from a multicenter，phase Ⅰb study [J]. J Clin Oncol，2017，35(19)：2117-2124.
[25] Khoja L，Butler MO，Kang SP，et al. Pembrolizumab [J]. J Immuno Ther Cancer，2015，3(1)：36.
[26] Bellmunt J，De wit R，Vaughn DJ，et al. KEYNOTE-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma [J]. New Engl J Med，2017，376(11)：1015-1026.
[27] Michot JM，Bigenwald C，Champiat S，et al. Immune-related adverse events with immune checkpoint blockade：a comprehensive review [J]. Eur J Cancer，2016，54：139-148.
[28] Weber JS，Kahler KC，Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab [J]. J Clin Oncol，2012，30(21)：2691-2697.
[29] Champiat S，Lambotte O，Barreau E，et al. Management of immune checkpoint blockade dysimmune toxicities：a collaborative position paper [J]. Ann Oncol，2015，27(4)：559-574.
(收稿日期：2019-07-24 本文編辑：李亚聪), http://www.100md.com(李彦泽 王磊 陈志远)